|
Relistor® (Methylnaltrexone Bromide) Data is Published in the Journal of Emergency Medicine
|
12/22/21
|
Relistor® (Methylnaltrexone Bromide) Data is Published in the Journal of Emergency Medicine
|
PDF
|
|
APMA Grants Seal of Approval for JUBLIA® (efinaconazole) Topical Solution, 10%
|
12/06/21
|
APMA Grants Seal of Approval for JUBLIA® (efinaconazole) Topical Solution, 10%
|
PDF
|
|
Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month
|
12/03/21
|
Salix Brings Educational Resources on Constipation Into the Homes of Patients and Caregivers for Constipation Awareness Month
|
PDF
|
|
Bausch + Lomb Reports More Than 41 Million Units Of Contact Lens, Eye And Lens Care Materials Recycled Through ONE By ONE And Biotrue® Eye Care Recycling Programs
|
11/15/21
|
Bausch + Lomb Reports More Than 41 Million Units Of Contact Lens, Eye And Lens Care Materials Recycled Through ONE By ONE And Biotrue® Eye Care Recycling Programs
|
PDF
|
|
Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021
|
11/11/21
|
Salix Will Share New Rifaximin Data At AASLD's The Liver Meeting™ 2021
|
PDF
|
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
11/04/21
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
|
Bausch Health Companies Inc. Announces Third-Quarter 2021 Results
|
11/02/21
|
Bausch Health Companies Inc. Announces Third-Quarter 2021 Results
|
pdf
|
|
Bausch + Lomb Will Present Scientific Data and Analyses During the American Academy of Ophthalmology and American Academy of Optometry Annual Meetings
|
11/01/21
|
Bausch + Lomb Will Present Scientific Data and Analyses During the American Academy of Ophthalmology and American Academy of Optometry Annual Meetings
|
PDF
|
|
Bausch + Lomb Launches Biotrue® Eye Care Recycling Program in Collaboration With TerraCycle in the United States
|
10/27/21
|
Bausch + Lomb Launches Biotrue® Eye Care Recycling Program in Collaboration With TerraCycle in the United States
|
PDF
|
|
New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States
|
10/25/21
|
New Report Reveals Barriers To Quality Care For Chronic Liver Disease Patients, A Cause Of Morbidity And Mortality Projected To Grow In The United States
|
PDF
|
|
Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting
|
10/25/21
|
Salix Will Feature New Data At The American College Of Gastroenterology® 2021 Annual Scientific Meeting
|
PDF
|
|
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
|
10/25/21
|
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
|
PDF
|
|
Bausch Health Announces Tom Vadaketh Will Join Bausch Pharma* As Chief Financial Officer
|
10/21/21
|
Bausch Health Announces Tom Vadaketh Will Join Bausch Pharma* As Chief Financial Officer
|
PDF
|
|
Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology Conference
|
10/19/21
|
Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology Conference
|
PDF
|
|
Bausch Health Companies Inc. Will Release Third-Quarter 2021 Financial Results On November 2
|
10/06/21
|
Bausch Health Companies Inc. Will Release Third-Quarter 2021 Financial Results On November 2
|
PDF
|
|
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction
|
09/30/21
|
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction
|
PDF
|
|
Bausch Health Releases Annual Environmental, Social and Governance Report
|
09/29/21
|
Bausch Health Releases Annual Environmental, Social and Governance Report
|
PDF
|
|
Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021
|
09/02/21
|
Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021
|
PDF
|
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
09/01/21
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
|
Bausch Health Companies Inc. Announces Second-Quarter 2021 Results
|
08/03/21
|
Bausch Health Companies Inc. Announces Second-Quarter 2021 Results
|
pdf
|
|
Bausch Health Announces Plans To Pursue An Initial Public Offering Of Solta Medical
|
08/03/21
|
Bausch Health Announces Plans To Pursue An Initial Public Offering Of Solta Medical
|
PDF
|
|
Bausch Health To Reduce Debt By $350 Million
|
08/03/21
|
Bausch Health To Reduce Debt By $350 Million
|
PDF
|
|
Bausch Health Completes Sale Of Amoun Pharmaceutical To ADQ
|
08/02/21
|
Bausch Health Completes Sale Of Amoun Pharmaceutical To ADQ
|
PDF
|
|
Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Recipients
|
07/29/21
|
Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Recipients
|
PDF
|
|
Salix Announces 2021 Gastrointestinal Health Scholars Program Winners
|
07/22/21
|
Salix Announces 2021 Gastrointestinal Health Scholars Program Winners
|
PDF
|
|
Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery
|
07/19/21
|
Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery
|
PDF
|
|
Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes
|
07/12/21
|
Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes
|
PDF
|
|
Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (perfluorohexyloctane)
|
07/07/21
|
Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (perfluorohexyloctane)
|
PDF
|
|
Bausch Health Companies Inc. Will Release Second-Quarter 2021 Financial Results On August 3
|
07/06/21
|
Bausch Health Companies Inc. Will Release Second-Quarter 2021 Financial Results On August 3
|
PDF
|
|
Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations
|
07/01/21
|
Bausch Health To Reduce Debt By $150 Million Using Cash Generated From Operations
|
PDF
|
|
Bausch + Lomb Expands Parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses
|
06/23/21
|
Bausch + Lomb Expands Parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses
|
PDF
|
|
Bausch Health Announces Extension Of Its Tender Offer For Cash Tender Offer For Senior Secured Notes By One Business Day To Reflect The Federal Holiday On June 18, 2021
|
06/22/21
|
Bausch Health Announces Extension Of Its Tender Offer For Cash Tender Offer For Senior Secured Notes By One Business Day To Reflect The Federal Holiday On June 18, 2021
|
PDF
|
|
Bausch Health Announces D. Robert Hale Has Resigned From Its Board Of Directors
|
06/21/21
|
Bausch Health Announces D. Robert Hale Has Resigned From Its Board Of Directors
|
PDF
|
|
Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software
|
06/08/21
|
Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software
|
PDF
|
|
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer For Senior Secured Notes
|
06/07/21
|
Bausch Health Announces Early Tender Results And Early Settlement Date For Cash Tender Offer For Senior Secured Notes
|
PDF
|
|
Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)
|
06/02/21
|
Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)
|
PDF
|
|
Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month
|
06/01/21
|
Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month
|
PDF
|
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
05/27/21
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
|
Bausch Health Announces Participation At The Jefferies Healthcare Conference
|
05/25/21
|
Bausch Health Announces Participation At The Jefferies Healthcare Conference
|
PDF
|
|
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes
|
05/24/21
|
Bausch Health Announces Pricing Of Private Offering Of Senior Secured Notes
|
PDF
|
|
Bausch Health Commences Cash Tender Offer For Any And All Of Its 7.00% Senior Secured Notes Due 2024
|
05/24/21
|
Bausch Health Commences Cash Tender Offer For Any And All Of Its 7.00% Senior Secured Notes Due 2024
|
PDF
|
|
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Conditional Redemption Of Existing Senior Secured Notes
|
05/24/21
|
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Conditional Redemption Of Existing Senior Secured Notes
|
PDF
|
|
Salix Will Feature New Data At Digestive Disease Week® 2021
|
05/17/21
|
Salix Will Feature New Data At Digestive Disease Week® 2021
|
PDF
|
|
New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced Age-Related Macular Degeneration Progression
|
05/11/21
|
New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced Age-Related Macular Degeneration Progression
|
PDF
|
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
05/06/21
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
|
Bausch Health Companies Inc. Announces First-Quarter 2021 Results
|
05/04/21
|
Bausch Health Companies Inc. Announces First-Quarter 2021 Results
|
pdf
|
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
05/03/21
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
|
Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During The Association For Research In Vision And Ophthalmology Meeting
|
04/29/21
|
Bausch + Lomb Will Present New Scientific Data And Analyses On Products And Pipeline Programs During The Association For Research In Vision And Ophthalmology Meeting
|
PDF
|
|
Bausch Health Announces 2021 Annual Meeting of Shareholder Results
|
04/28/21
|
Bausch Health Announces 2021 Annual Meeting of Shareholder Results
|
PDF
|
|
Bausch Health Issues Form 8-K for 2021 Annual Meeting of Shareholders Presentation
|
04/27/21
|
Bausch Health Issues Form 8-K for 2021 Annual Meeting of Shareholders Presentation
|
PDF
|
|
Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris
|
04/22/21
|
Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating IDP-126 Gel In Acne Vulgaris
|
PDF
|
|
Ortho Dermatologics to Present New Data at the AAD VMX 2021, Virtual Meeting Experience
|
04/21/21
|
Ortho Dermatologics to Present New Data at the AAD VMX 2021, Virtual Meeting Experience
|
PDF
|
|
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved In Brazil
|
04/16/21
|
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved In Brazil
|
PDF
|
|
New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic
|
04/15/21
|
New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic
|
PDF
|
|
Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
|
04/13/21
|
Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
|
PDF
|
|
Bausch Health Companies Inc. Will Release First-Quarter 2021 Financial Results On May 4
|
04/09/21
|
Bausch Health Companies Inc. Will Release First-Quarter 2021 Financial Results On May 4
|
PDF
|
|
Bausch Health Launches ENVIVE™ Daily Probiotic Supplement
|
04/08/21
|
Bausch Health Launches ENVIVE™ Daily Probiotic Supplement
|
PDF
|
|
FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device
|
04/07/21
|
FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device
|
PDF
|
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
04/07/21
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
|
Bausch Health Agrees To Sell Amoun Pharmaceuticals
|
03/31/21
|
Bausch Health Agrees To Sell Amoun Pharmaceuticals
|
PDF
|
|
Salix Launches GastroHub for Advanced Practice Providers, an Educational Website Designed To Provide Nurse Practitioners and Physician Assistants With Relevant Information for Treating IBS-D and HE
|
03/30/21
|
Salix Launches GastroHub for Advanced Practice Providers, an Educational Website Designed To Provide Nurse Practitioners and Physician Assistants With Relevant Information for Treating IBS-D and HE
|
PDF
|
|
Bausch Health Announces CFO Succession Plan
|
03/11/21
|
Bausch Health Announces CFO Succession Plan
|
PDF
|
|
Bausch Health Publishes Pipeline Update For The Barclays Global Healthcare Conference
|
03/09/21
|
Bausch Health Publishes Pipeline Update For The Barclays Global Healthcare Conference
|
PDF
|
|
Solta Medical Announces the U.S. Launch of The Clear + Brilliant® Touch Laser
|
03/08/21
|
Solta Medical Announces the U.S. Launch of The Clear + Brilliant® Touch Laser
|
PDF
|
|
Colon Cancer Coalition and Salix to Launch a Year-Long Campaign to Raise Awareness About the Importance of Colorectal Cancer Screenings
|
03/01/21
|
Colon Cancer Coalition and Salix to Launch a Year-Long Campaign to Raise Awareness About the Importance of Colorectal Cancer Screenings
|
pdf
|
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
02/26/21
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance
|
02/24/21
|
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance
|
pdf
|
|
Bausch Health Announces Agreement With Carl C. Icahn
|
02/24/21
|
Bausch Health Announces Agreement With Carl C. Icahn
|
PDF
|
|
Bausch + Lomb Launches Alaway® Preservative Free Antihistamine Eye Drops
|
02/23/21
|
Bausch + Lomb Launches Alaway® Preservative Free Antihistamine Eye Drops
|
PDF
|
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
02/22/21
|
Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations
|
PDF
|
|
Salix Announces 2021 Gastrointestinal Health Scholars Program
|
02/18/21
|
Salix Announces 2021 Gastrointestinal Health Scholars Program
|
PDF
|
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
02/16/21
|
Bausch Health Announces Participation In Upcoming Investor Conferences
|
PDF
|
|
Bausch Health Responds To Schedule 13D Filing From Icahn Capital LP
|
02/11/21
|
Bausch Health Responds To Schedule 13D Filing From Icahn Capital LP
|
PDF
|
|
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea
|
02/09/21
|
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea
|
PDF
|
|
Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Program
|
02/02/21
|
Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Program
|
PDF
|
|
Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Age-Related Macular Degeneration (AMD)
|
02/01/21
|
Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Age-Related Macular Degeneration (AMD)
|
PDF
|
|
Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2020 Financial Results On February 24
|
01/27/21
|
Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2020 Financial Results On February 24
|
PDF
|
|
South Korea's MFDS Approves LUMIFY® Eye Drops
|
01/21/21
|
South Korea's MFDS Approves LUMIFY® Eye Drops
|
PDF
|
|
Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium
|
01/20/21
|
Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium
|
PDF
|
|
Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (perfluorohexyloctane)
|
01/19/21
|
Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (perfluorohexyloctane)
|
PDF
|
|
Bausch Health Provides Preliminary Update On Fourth-Quarter And Full-Year 2020 Financial Results And Business Recovery
|
01/12/21
|
Bausch Health Provides Preliminary Update On Fourth-Quarter And Full-Year 2020 Financial Results And Business Recovery
|
PDF
|
|
Bausch Health To Participate At The 39th Annual J.P. Morgan Healthcare Conference
|
01/06/21
|
Bausch Health To Participate At The 39th Annual J.P. Morgan Healthcare Conference
|
PDF
|
